Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_3
1
20%
Ph phase_4
2
40%
Ph phase_2
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Not yet recruiting1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)

Trials by Status

completed240%
not_yet_recruiting120%
terminated120%
recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
not_yet_recruiting

Omalizumab for Plant-Food Allergy Due to Sensitization to LTP or Profilin

NCT07073404
recruitingphase_4

Effect of Omalizumab in the Skin of Food Allergy Patients

NCT06618963
completedphase_2

Treatment With the Anti-IgE Monoclonal Antibody Omalizumab in Women With Asthma Undergoing Fertility Treatment. - A Proof of Concept Study.

NCT03727971
completedphase_3

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

NCT05774639
terminatedphase_4

Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).

NCT03964051

Clinical Trials (5)

Showing 5 of 5 trials
NCT07073404

Omalizumab for Plant-Food Allergy Due to Sensitization to LTP or Profilin

Not Yet Recruiting
NCT06618963Phase 4

Effect of Omalizumab in the Skin of Food Allergy Patients

Recruiting
NCT03727971Phase 2

Treatment With the Anti-IgE Monoclonal Antibody Omalizumab in Women With Asthma Undergoing Fertility Treatment. - A Proof of Concept Study.

Completed
NCT05774639Phase 3

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

Completed
NCT03964051Phase 4

Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5